Sasanka M Handunnetti
9PUBLICATIONS
32CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (9)
Sort by Publication Date:
|Dec 11, 2025
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.Sasanka M Handunnetti, Amit Khot, Piers Blombery
|Jul 27, 2025
Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in Australia.Stephen P Mulligan, Philip A Thompson, Joel Wight
|Apr 25, 2024
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.Sasanka M Handunnetti, Mary Ann Anderson, Kate Burbury
|Jan 17, 2024
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.Thomas E Lew, Rory Bennett, Victor S Lin
|Jul 28, 2022
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.Piers Blombery, Ella R Thompson, Thomas E Lew
|Dec 03, 2021
Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors.Ella R Thompson, Tamia Nguyen, Yamuna Kankanige
Pageof 2
Frequent Collaborators
7 joint publications
Constantine S Tam
7 joint publications
John F Seymour
4 joint publications
Thomas E Lew
4 joint publications
Philip A Thompson
4 joint publications
Andrew W Roberts
3 joint publications
Victor S Lin
3 joint publications
Mary Ann Anderson
2 joint publications
Stephen P Mulligan
2 joint publications
Ella R Thompson
2 joint publications
David C S Huang
